3B BlackBio Dx Ltd — Important, 13-11-2025: Company Update

The company announced strong consolidated H1 financial results, with revenue reaching 56.14 Cr and profit after tax at 27.68 Cr, resulting in an EPS of 32.31 Rs. This growth was boosted by the molecular diagnostics segment's performance, which included 3.63 Cr from the strategic acquisition of Coris Bioconcept SRL for £2.765 Million. This acquisition enhances the company's IVD and anti-microbial resistance solutions. Moving forward, the company is actively expanding globally, pursuing further M&A, and innovating with new diagnostic technologies like Digital PCR and rapid AMR tests, projecting 20-25% export growth.